HeartBeam to Present FDA-Cleared Cardiac Technology at JP Morgan Healthcare Conference

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, will attend the JP Morgan 2026 Annual Healthcare Conference from January 12 to 15, 2026, at the Westin St. Francis Hotel in San Francisco. Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available for off-site meetings with investors and potential commercialization and co-development partners from January 12 to 14.

The company's participation comes shortly after receiving 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment. This regulatory milestone precedes a planned limited U.S. commercial launch in the first quarter of 2026. HeartBeam's technology represents a significant advancement in cardiac monitoring as it creates the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing those signals into a 12-lead ECG.

This platform technology is designed for portable devices that can be used wherever patients are located, delivering actionable heart intelligence to physicians. The system enables healthcare providers to identify cardiac health trends and acute conditions while directing patients to appropriate care outside traditional medical facilities. The technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-Lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to this technology enablement.

The HeartBeam System functions as a portable non-invasive recorder intended to record, store, and transfer a patient's 3-lead ECG acquired from five electrodes. The device is designed for adult patients in either clinical settings or at home and does not conduct cardiac analysis independently. Instead, it works with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by physicians or healthcare professionals. The 12-Lead ECG Synthesis Software synthesizes a 12-lead ECG from the HeartBeam System's 3-lead recording device, producing a visual representation similar to standard diagnostic 12-lead ECGs.

This synthesized output is intended solely for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The software explicitly excludes assessment of other arrhythmias or conditions such as ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, localization of arrhythmia foci, ECG wave abnormalities, and other disorders. The technology is not intended to replace standard 12-lead ECGs and is designed for adult use only.

The implications of HeartBeam's technology extend beyond the immediate medical applications. By enabling cardiac monitoring outside traditional healthcare facilities, this innovation could potentially reduce healthcare costs associated with hospital visits while improving patient access to cardiac care. The portable nature of the device allows for more frequent monitoring, potentially leading to earlier detection of cardiac issues and more timely interventions. For the medical technology industry, HeartBeam's approach represents a shift toward decentralized healthcare monitoring solutions that leverage software synthesis to reduce hardware complexity.

Investors and potential partners attending the JP Morgan Healthcare Conference will have the opportunity to learn more about HeartBeam's commercialization strategy and technological capabilities. The company's presence at this prestigious industry event signals its readiness to engage with the investment community and establish partnerships that could accelerate market adoption of its cardiac monitoring solutions. Additional information about HeartBeam is available through the company's website at https://HeartBeam.com, while updates relating to BEAT are accessible in the company's newsroom at https://nnw.fm/BEAT.